Liposome Program
Breast Cancer
Key Facts
About NanoTech Pharma
NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.
View full company profileAbout NanoTech Pharma
NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.
View full company profileAbout NanoTech Pharma
NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.
View full company profileAbout NanoTech Pharma
NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.
View full company profileAbout NanoTech Pharma
NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |
| GCT-007 | Global Cancer Technology | Research |
| NDES | Continuity Biosciences | Pre-clinical |